homepage-top-section

The monoclonal antibody is being investigated to reduce the risk of major thrombotic cardiovascular events in ESRD patients MK-2060 is a new Factor XI inhibitor and has been designed to

The vaccine has been approved for preventing dengue disease in people aged six years to 45 years. Qdenga has been developed based on a live-attenuated dengue serotype 2

Auvelity is claimed to be the first and only oral N-methyl D-aspartate (NMDA) receptor antagonist with multimodal activity that has been approved to treat MDD. It is said

The regulator has approved Pepaxti in combination with dexamethasone to treat adult multiple myeloma patients who have received at least three lines of therapies previously, whose disease is

The latest move follows a definitive merger agreement signed by the companies for the transaction in June. As announced previously, Bristol Myers Squibb purchased all outstanding shares of

Flagship Pioneering took part in the financing round, which has also seen participation from new investors, including Bluwave Capital, Qatar Investment Authority (QIA), Stage 1 Ventures, and Samsung

The latest move follows a positive opinion issued by the European Medicines Agency (EMA). A precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody, INBRX-109 has been designed for

Orally available bruton’s tyrosine kinase (BTK) inhibitor, orelabrutinib irreversibly binds to BTK for inducing downstream kinase inactivation and cell death. It has been designed with a single ring

Xofluza is indicated to treat acute uncomplicated influenza in healthy children aged five to less than 12 years with symptoms for not over 48 hours. The regulatory approval